Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IONSthis companyIonis Pharmaceuticals, Inc.	$28.19	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
ALNYAlnylam Pharmaceuticals, Inc.	$155.89	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
BBIOBridgeBio Pharma, Inc.	$74.41	-20.18×	-7.27×	30.05×	-25.49×	-271.4%	94.4%	-113.3%	-145.3%	35.1%	-108.5%	-3.0%	-1.31×	-3.19×	-10.72×	2.62×	0.0%	2	-0.07	2	C
BIIBBiogen Inc.	$253.70	19.89×	1.41×	2.63×	10.1×	102.9%	70.5%	19.1%	13.2%	7.1%	6.6%	7.9%	0.38×	1.34×	7.63×	2.68×	0.0%	5	3.15	3	B
BMRNBioMarin Pharmaceutical Inc.	$55.98	32.65×	1.87×	3.54×	18.73×	-87.5%	77.1%	16.6%	10.8%	5.7%	5.6%	6.4%	0.11×	-1.17×	48.95×	5.21×	0.0%	3	0.33	3	B
NTLAIntellia Therapeutics, Inc.	$11.85	-2.36×	1.45×	14.4×	-2.3×	-249.6%	76.5%	-651.7%	-609.9%	-61.5%	-57.7%	-36.4%	0.14×	0.16×	0×	5.08×	0.0%	4	2.17	2	C
Peer median	—	19.89×	1.45×	14.03×	10.1×	-249.6%	77.1%	13.5%	8.4%	7.1%	5.6%	0.9%	0.14×	-0.6×	1.99×	2.76×	0.0%	4	2.17	3	—